Human-led · Source-checked

Biotech & Pharma Intelligence

Edition 053 · Sun 11.22.2026

Special Coverage: The State of Biotech

Special Coverage: The State of Biotech. FDA turned down Capricor’s Duchenne cell therapy a second time; Merck says its TROP2 drug extended survival.

Read the full brief

Five things for the weekend

  1. Special CoverageSpecial Coverage: The State of BiotechOur state of the union for biotech as the year turns: share prices are falling alongside the AI trade, while FDA has approved 55 new drugs this year. We test the thesis against its strongest alternative and close with a playbook for CEOs, boards and allocators before JPM. FDA novel approvals, 2026#
  2. Must readFDA turned down Capricor’s deramiocel in Duchenne muscular dystrophy a second time.FDA’s own statement cites “serious data integrity violations” in HOPE-3; Capricor says both of its trials met their primary endpoints.Match NCT06356311 registers overall survival as the single primary outcome, with progression-free survival, response rate and duration of response by blinded central review as secondaries, and 473 enrolled;#
  3. Must readMerck says sac-TMT improved overall survival in third-line gastroesophageal cancer in the Phase 3 TroFuse-015.Progression-free survival, a secondary endpoint, wasn’t met, and no hazard ratio was released.Partial NCT04585750 registers the Phase 2 primaries as response rate in the ovarian cohort and across all cohorts, both as assessed by independent review; the release reports investigator-assessed responses, #
  4. Know itPMV’s rezatapopt drew responses in 48% of 65 women with platinum-resistant or refractory ovarian cancer.It’s a single-arm trial with investigator-assessed responses; PMV plans an accelerated approval filing in the first quarter of 2027.#
  5. Know itFDA will miss Savara’s 11.22 goal date for molgramostim in autoimmune PAP.The review continues, with no new date given.#
  6. ScanFriday’s money was closings, not new deals: Avenzo’s $215M placement and SELLAS’s $172.5M offering.The Sanofi and Insmed report remains unconfirmed by either company.#

Bright spot

In the randomized RT CHARM trial, 16 radiation sessions after mastectomy and reconstruction were noninferior to 25 on complications at 24 months, per ASCO Post’s report: nine fewer trips to the clinic.

Verified today #

Claim Check #

Readout Registry says Headline says Verdict
Sac-TMT TroFuse-015 · Merck NCT06356311 Phase 3. Primary: overall survival. Secondaries include PFS by blinded central review. N=473. Met overall survival at final analysis; PFS secondary not met; no hazard ratio released Match
Rezatapopt PYNNACLE · PMV NCT04585750 Phase 1/2. Phase 2 primaries: response rate by independent review, ovarian cohort and all cohorts. 300 planned; recruiting. Investigator-assessed response 48% (31 of 65) in platinum-resistant or refractory ovarian cancer; 36% of 168 overall Partial

Calendar #

Date Event Who Confirmed at
2026-11-23 Conference call on the deramiocel complete response letter, 8:30 am ET Capricor Company
2026-11-23 KT-621 BROADEN2 Phase 2b results in atopic dermatitis Kymera Company
2026-11-25 GDP, third quarter second estimate, and corporate profits BEA Gov
2026-11-25 Personal income and outlays for October, including PCE prices BEA Gov
2026-11-25 Beige Book Federal Reserve Fed
2026-11-26 Thanksgiving: federal offices closed Federal Reserve Fed
2026-11-27 NDA goal date, priority review: BBP-418 in LGMD2I/R9 BridgeBio Company
2026-11-28 NDA goal date, priority review: D-PLEX100 in colorectal surgery PolyPid Company
2026-11-29 RSNA Annual Meeting opens, Chicago RSNA Organizer
2026-11-30 Goal date, priority review: giredestrant adjuvant (lidERA) Roche Company
2026-11-30 BLA goal date, accelerated approval: povetacicept in IgA nephropathy Vertex Company
2026-11-30 NDA goal date, priority review: bezuclastinib with sunitinib in GIST Cogent Company
2026-11-30 Deadline to publish negotiated prices for the 15 drugs selected for 2028 CMS CMS

Money Map #

Week Deals Total Largest deals
10.19 to 10.25 12 $2,217M Disc Medicine, Lycia, Arcus
10.26 to 11.01 11 $1,393M Dren Bio, Corxel US, Rapport
11.02 to 11.08 11 $679M T-Therapeutics, Precision BioSciences, Alethio
11.09 to 11.15 17 $1,286M Windward Bio, Vir, Prime Medicine
11.16 to 11.22 8 $5,540M Isomorphic Labs ($5,000M), SELLAS ($150M), Marrow ($120M)

Therapeutic Area Pulse #

Therapeutic area Evidence Coverage Items Confidence What drove it
Oncology +1.2 +0.4 11 · 16 HIGH Approvals for Wilserdly and Nelkarmi and survival wins for SELLAS and Merck’s sac-TMT, against Merck’s nemtabrutinib stop and coverage of Summit’s rejection letter
Immunology & inflammation -0.2 0.0 4 · 6 MED Livsayis approved in myasthenia gravis, against two eczema misses, Aclaris’s bosakitug and Celldex’s barzolvolimab
Metabolic & obesity · 0.0 0 · 3 LOW Seawolf’s $100M launch not scored; coverage only: lower-dose CagriSema, the compounded GLP-1 debate and trial design
Neuroscience -0.5 0.0 4 · 7 MED Helus’s Phase 3 win in depression, against Actinogen’s Phase 2b/3 miss and AriBio’s overall-population miss in Alzheimer’s
Cardiovascular & renal QUIET QUIET 0 · 1 · Fewer than three scored items this week
Rare & genetic +0.4 +0.3 5 · 7 HIGH Two approvals, Lembaz and Infilbray, against FDA’s second rejection of Capricor’s deramiocel and the missed Savara date
Gene, cell & editing +1.0 +1.0 1 · 3 LOW Pfizer’s in vivo CAR-T license from Starna and coverage of a profitable genetic medicines business
Infectious disease & vaccines QUIET QUIET 1 · 0 · Fewer than three scored items this week
Other & platform +1.0 +1.0 2 · 2 LOW Isomorphic’s $5B round and Lilly’s Stipple pact

Download the full briefPDF, 33 pages

Track record: our calls, graded in public · corrections log

Want this by email? Join Mind Club. It's complimentary.